Horizon Pharma plc (Nasdaq: HZNP) to Ring The Nasdaq Stock Market Opening Bell


ADVISORY, Jan. 23, 2015 (GLOBE NEWSWIRE) --

What: 

Horizon Pharma plc (Nasdaq:HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, will visit the Nasdaq MarketSite in Times Square. 

In honor of the occasion, Timothy P. Walbert, chairman, president & chief executive officer, Horizon Pharma plc, will ring the Opening Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Monday, January 26, 2015 – 9:15 a.m. to 9:30 a.m. ET   

Horizon Pharma Media Contact:

Geoff Curtis
(312) 233-1253
Geoff.Curtis@djescience.com  

Horizon Pharma Investor Contact:

Elizabeth M. Higashi, CFA
(224) 383-3285
investor-relations@horizonpharma.com 

Nasdaq MarketSite:

Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Horizon Pharma plc (Nasdaq:HZNP):

Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs.  The Company markets a portfolio of products in arthritis, inflammation and orphan diseases.  Horizon's U.S. marketed products are ACTIMMUNE® (interferon gamma-1b), DUEXIS® (ibuprofen/famotidine), PENNSAID® (diclofenac sodium topical solution) 2% w/w, RAYOS® (prednisone) delayed-release tablets and VIMOVO® (naproxen/esomeprazole magnesium).  Horizon's global headquarters are in Dublin, Ireland.  For more information, please visit www.horizonpharma.com.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.  As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

-NDAQA-


Tags